Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Keisuke Okamura, Yosuke Takamiya, Ken Mori, Kazuyuki Shirai & Hidenori Urata. (2020) Add-on aliskiren treatment can decrease blood pressure but requires attention to risks of renal impairment and hyperkalemia Chikushi Anti-Hypertension Trial-Rasilez® (CHAT-Ras). Clinical and Experimental Hypertension 42:6, pages 545-552.
Read now
Read now
Fabio Angeli, Gianpaolo Reboldi, Giovanni Mazzotta, Cristina Poltronieri & Paolo Verdecchia. (2012) Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. Expert Opinion on Drug Safety 11:4, pages 659-670.
Read now
Read now
Hernán Trimarchi. (2011) Role of aliskiren in blood pressure control and renoprotection. International Journal of Nephrology and Renovascular Disease 4, pages 41-48.
Read now
Read now
Maurizio Destro, Francesca Cagnoni, Giuseppina Patrizia Dognini, Vincenzo Galimberti, Carlo Taietti, Chiara Cavalleri & Emilio Galli. (2011) Telmisartan: just an antihypertensive agent? A literature review. Expert Opinion on Pharmacotherapy 12:17, pages 2719-2735.
Read now
Read now
Benjamin J Epstein. (2010) Aliskiren and valsartan combination therapy for the management of hypertension. Vascular Health and Risk Management 6, pages 711-722.
Read now
Read now
Steven G. Chrysant, Alexander V. Murray, Uta C. Hoppe, Dan Dattani, Samir Patel, Shannon Ritter & Jack Zhang. (2010) Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Current Medical Research and Opinion 26:12, pages 2841-2849.
Read now
Read now
J. Signorovitch, J. Zhang, E.Q. Wu, D. Latremouille-Viau, A.P. Yu, H.B. Dastani & K.H. Kahler. (2010) Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. Current Medical Research and Opinion 26:4, pages 849-860.
Read now
Read now
Steven A Yarows. (2010) Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert Review of Cardiovascular Therapy 8:1, pages 19-33.
Read now
Read now
Benjamin J Epstein, Steven M Smith & Rushab Choksi. (2009) Recent changes in the landscape of combination RAS blockade. Expert Review of Cardiovascular Therapy 7:11, pages 1373-1384.
Read now
Read now
Rainer Düsing & Felicity Sellers. (2009) ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Current Medical Research and Opinion 25:9, pages 2287-2301.
Read now
Read now
Raymond O. Estacio. (2009) Renin-Angiotensin-Aldosterone System Blockade in Diabetes: Role of Direct Renin Inhibitors. Postgraduate Medicine 121:3, pages 33-44.
Read now
Read now
Kalathil K Sureshkumar. (2008) Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy. Vascular Health and Risk Management 4:6, pages 1205-1220.
Read now
Read now
Articles from other publishers (24)
Joel M. Neutel, Thomas D. Giles, Henry Punzi, Robert J. Weiss, Huiling Li & Amy Finck. (2014) Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. Journal of the American Society of Hypertension 8:12, pages 915-920.
Crossref
Crossref
Gowraganahalli Jagadeesh, Pitchai Balakumar & Norman Stockbridge. (2012) How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?. Cellular Signalling 24:8, pages 1583-1591.
Crossref
Crossref
Samir G Mallat. (2012) What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?. Cardiovascular Diabetology 11:1, pages 32.
Crossref
Crossref
Anjay Rastogi, Mohamad Rashid & Richard F. Wright. (2011) Reducing Cardiorenal Risk Through Combination Therapy With a Direct Renin Inhibitor. The Journal of Clinical Hypertension 13:11, pages 848-855.
Crossref
Crossref
William B. White, Robert Bresalier, Allen P. Kaplan, Biff F. Palmer, Robert H. Riddell, Anastasia Lesogor, William Chang & Deborah L. Keefe. (2011) Safety and Tolerability of the Direct Renin Inhibitor Aliskiren in Combination With Angiotensin Receptor Blockers and Thiazide Diuretics: A Pooled Analysis of Clinical Experience of 12,942 Patients. The Journal of Clinical Hypertension 13:7, pages 506-516.
Crossref
Crossref
Natale Daniele BrunettiLuisa De GennaroPier Luigi PellegrinoAndrea CuculoLuigi ZiccardiAntonio GaglioneMatteo Di Biase. (2011) Direct renin inhibition: update on clinical investigations with aliskiren. European Journal of Cardiovascular Prevention & Rehabilitation 18:3, pages 424-437.
Crossref
Crossref
Fadi G Hage, Sulaf J Mansur & Suzanne Oparil. (2011) Rationale for the use of multiple blockers of the renin–angiotensin–aldosterone system in specific patient populations. Therapy 8:3, pages 227-236.
Crossref
Crossref
D. Richter, C. Mickel, S. Acharya, P. Brunel & C. Militaru. (2011) Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control. International Journal of Clinical Practice 65:5, pages 613-623.
Crossref
Crossref
Erin Elizabeth Kelland, Leanne Michelle McAuley & Guido Filler. (2010) Are we ready to use aliskiren in children?. Pediatric Nephrology 26:3, pages 473-477.
Crossref
Crossref
Helmy M. Siragy. (2011) Rationale for Combining a Direct Renin Inhibitor with other Renin- Angiotensin System Blockers. Focus on Aliskiren and Combinations. Cardiovascular Drugs and Therapy 25:1, pages 87-97.
Crossref
Crossref
Sulaf J. Mansur, Fadi G. Hage & Suzanne Oparil. (2010) Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?. Current Cardiology Reports 12:6, pages 450-463.
Crossref
Crossref
Sean T. Duggan, Claudine M. Chwieduk & Monique P. Curran. (2010) Aliskiren. Drugs 70:15, pages 2011-2049.
Crossref
Crossref
William B. White, Robert Bresalier, Allen P. Kaplan, Biff F. Palmer, Robert H. Riddell, Anastasia Lesogor, William Chang & Deborah L. Keefe. (2010) Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension. The Journal of Clinical Hypertension 12:10, pages 765-775.
Crossref
Crossref
Christian Werner, Janine Pöss & Michael Böhm. (2010) Optimal Antagonism of the Renin-Angiotensin-Aldosterone System. Drugs 70:10, pages 1215-1230.
Crossref
Crossref
Christian W. Mende. (2010) Application of Direct Renin Inhibition to Chronic Kidney Disease. Cardiovascular Drugs and Therapy 24:2, pages 139-149.
Crossref
Crossref
Steven G. Chrysant. (2010) Current Status of Dual Renin Angiotensin Aldosterone System Blockade for the Treatment of Cardiovascular Diseases. The American Journal of Cardiology 105:6, pages 849-852.
Crossref
Crossref
Carlos M. Ferrario. (2010) Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin–angiotensin–aldosterone system: Antihypertensive effects and benefits beyond BP control. Life Sciences 86:9-10, pages 289-299.
Crossref
Crossref
Dimitris P. PapadopoulosVasilios PapademetriouThomas K. Makris. (2009) On Target to Dual Block RAS?. Angiology 60:6, pages 739-749.
Crossref
Crossref
Hiddo J Lambers Heerspink, Vlado Perkovic & Dick de Zeeuw. (2009) Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. Journal of Hypertension 27:12, pages 2321-2331.
Crossref
Crossref
C Venkata S Ram. (2009) Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. Future Cardiology 5:5, pages 453-465.
Crossref
Crossref
Peter S SeverAlan H Gradman & Michel Azizi. (2009) Managing cardiovascular and renal risk: the potential of direct renin inhibition. Journal of the Renin-Angiotensin-Aldosterone System 10:2, pages 65-76.
Crossref
Crossref
Carlos M. Ferrario, Jewell A. Jessup & Jasmina Varagic. 2009. The Local Cardiac Renin-Angiotensin Aldosterone System. The Local Cardiac Renin-Angiotensin Aldosterone System
7
17
.
Steven A. Yarows, Suzanne Oparil, Samir Patel, Hui Fang & Jack Zhang. (2008) Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Advances in Therapy 25:12, pages 1288-1302.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:10.
Crossref
Crossref